TABLE 1.
Glycopeptide resistance phenotypes and genotypes of chicken and human VRE isolates
| VRE (no. of isolates) | Source | MIC (μg/ml) (interpretation a) of:
|
Phenotype | Genotype | |
|---|---|---|---|---|---|
| Vancomycin | Teicoplanin | ||||
| E. faecalis (27) | Chicken | ≥1,024 (R) | 0.75–8 (S) | VanB | vanA |
| E. faecium (12) | Chicken | ≥1,024 (R) | 0.25–1.0 (S) | VanB | vanA |
| E. faecalis (4) | Human | >1,024 (R) | 2–8 (S) | VanB | vanA |
| E. faecalis (3) | Human | >1,024 (R) | 12 (I) | VanB? | vanA |
| E. faecium (3) | Human | 512–1,024 (R) | 0.75–1.0 (S) | VanB | vanB |
| E. faecium (7) | Human | >1,024 (R) | 24 (R) | VanA | vanA |
a
Interpretive criteria based on National Committee for Clinical Laboratory Standards. S, susceptible; I, intermediate; R, resistant. Interpretations for vancomycin: S, ≤4 μg/ml; I, 8 to 16 μg/ml; R, ≥32 μg/ml. Interpretations for teicoplanin: S, ≤8 μg/ml; I, 16 μg/ml; R, ≥32 μg/ml.